HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Sun Yat-sen University
Updated on 27 January 2023

Summary

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

Description

Hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin was effective and safe for hepatocellular carcinoma. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and Sintilimab, an programmed cell death protein-1 (PD-1) antibody, was effective and tolerable in patients with hepatocellular carcinoma and portal vein tumor thrombus. No study has evaluated HAIC plus Lenvatinib and Sintilimab. Thus, the investigators carried out this prospective, single-arm study to find out it.

Details
Condition LIVER DISEASE, LIVER DISEASE, Liver Disorders, HEPATIC NEOPLASM, Liver Cancer, Neoplasm of unspecified nature of digestive system, Digestive System Neoplasms, HEPATOCELLULAR CARCINOMA, Portal Vein Tumor Thrombus, Liver Cancer, Liver Disorders, Digestive System Neoplasms, Sintilimab, hepatoma, tumor liver, liver tumor, liver tumours, liver cell carcinoma
Treatment Lenvatinib, Hepatic arterial infusion chemotherapy, Sintilimab
Clinical Study IdentifierNCT04618367
SponsorSun Yat-sen University
Last Modified on27 January 2023

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note